TICKERNERD
Menu
QTRXQTRXHealthcare · Medical Devices

QTRX Stock Forecast: Quanterix Corp. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$2.99
−4.17% on the day

The 3 Wall Street analysts covering Quanterix Corp. hold a median 12-month price target of $3 — +0.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$141.4M
Ticker Nerd rank
28 / 100
Median analyst target
$3.00
Analysts covering
3
Total return, dividends reinvested
1W
+15.4%
1M
−24.7%
YTD
−53.0%
1Y
−38.2%
From 52W high
−62.9%
From 52W low
+23.6%
$2.42
$8.06
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

QTRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Quanterix Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
28 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
72
Growth
58
Accruals
52
Volatility
50
Issuance
49
Quality
41
Value
32
Revisions
26
Momentum
16

Size (72): Smaller than most of the companies we track.

Momentum (16): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

QTRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on QTRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$3.00$4.00$5.00$6.00$7.00$8.00Oct 25Jan 26Apr 26Jul 26QTRXHigh $3.00Median $3.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says3 analysts
0 Buy3 Hold0 Sell
Low $3.00Median $3.00High $3.00

The green dot is the last close — the median target sits +0.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
17 Aug 2026Canaccord GenuityMaintainsHold$4.00 → $3.00
11 Aug 2026TD CowenMaintainsHold$4.00 → $3.00
7 May 2026TD CowenMaintainsHold$7.00 → $4.00
7 May 2026TD CowenMaintainsHold—
20 Apr 2026Canaccord GenuityMaintainsHold—
22 Dec 2025Canaccord GenuityMaintainsHold—
11 Aug 2025Canaccord GenuityDowngradeHold—
13 May 2025Canaccord GenuityMaintainsBuy—
30 Apr 2025Leerink PartnersDowngradeMarket Perform—
25 Mar 2025ScotiabankMaintainsSector Outperform—
18 Mar 2025Canaccord GenuityMaintainsBuy—
13 Nov 2024TD CowenMaintainsHold—
12 Aug 2024ScotiabankMaintainsSector Outperform—
9 Aug 2024TD CowenMaintainsHold—
9 July 2024Goldman SachsMaintainsBuy—
29 Apr 2024Canaccord GenuityMaintainsBuy—
4 Mar 2024ScotiabankMaintainsSector Outperform—
28 Sept 2023Goldman SachsMaintainsBuy—
27 Sept 2023Goldman SachsMaintainsBuy—
25 Sept 2023Canaccord GenuityUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. QTRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

QTRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Quanterix Corp. (QTRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.2×

Cheaper than 83% of US stocks

Price / sales
0.9×

Cheaper than 71% of US stocks

Price / book
0.6×

Cheaper than 83% of US stocks

EV / EBITDA
−1.2×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
34.4%

Higher than 81% of US stocks

Earnings growth (YoY)
20.3%

Higher than 59% of US stocks

Gross margin
42.7%

Higher than 54% of US stocks

Operating margin
−68.4%

Higher than 15% of US stocks

Net margin
−80.2%

Higher than 7% of US stocks

Returns & dividend
Return on equity
−46.5%

Higher than 22% of US stocks

Return on assets
−16.7%

Higher than 22% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

QTRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
QTRXQuanterix Corp.$141.4M
28
MXCTMaxCyte, Inc.$147.8M
72
OWLTOwlet, Inc.$150.8M
34
INGNInogen, Inc.$152.8M
86
APYXApyx Medical Corp.$128.0M
70
QSIQuantum-Si, Inc.$179.9M
31
LNSRLENSAR, Inc.$103.6M
60

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Quanterix Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest QTRX news & analysis

Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer's Blood Test

MarketBeat · 16 Aug 2026neutral

Quanterix CEO Everett Cunningham said the company is repositioning its commercial organization and investing in diagnostics and clinical-trial capabilities following the integration of Akoya Biosciences. He also acknowledged continued market pressure in academic, government and biopharma segments.

Why it matters — QTRX watchers would care because the company is restructuring its sales strategy and hinting at a possible Q4 FDA decision for its Alzheimer's blood test amid persistent demand headwinds in key markets.

Quanterix Corporation (QTRX) Q2 2026 Earnings Call Transcript

Seeking Alpha · 10 Aug 2026neutral

Quanterix Corporation held its Q2 2026 earnings call, and the full transcript of that call was published by Seeking Alpha. The transcript covers the company's second-quarter 2026 results and discussion.

Why it matters — A QTRX watcher would use this transcript to review the company's latest quarterly performance and management commentary directly from the earnings call.

Quanterix Q2 Earnings Call Highlights

MarketBeat · 10 Aug 2026negative

Quanterix reported second-quarter 2026 revenue of $32.9 million, roughly $3 million (9%) below the guidance it provided in May. Management lowered the full-year outlook, citing broad-based market softness and commercial execution challenges.

Why it matters — QTRX watchers would care because the company fell short of its own guidance and cut its full-year outlook, signaling weaker near-term performance.

Quanterix Names Jim Gute Chief Commercial Officer

Business Wire · 10 Aug 2026positive

Quanterix Corporation announced the appointment of Jim Gute as Chief Commercial Officer. Gute, a seasoned healthcare executive, will lead a re-acceleration of growth in the company's commercial operations, ahead of its expansion in diagnostics.

Why it matters — A new commercial leader signals a renewed focus on accelerating growth and advancing Quanterix's diagnostics expansion, which QTRX watchers would follow closely.

Quanterix Releases Financial Results for the Second Quarter of 2026

Business Wire · 10 Aug 2026negative

Quanterix announced its financial results for the second quarter ended June 30, 2026, noting progress in strengthening its leadership team and preserving cash better than planned. However, revenue fell short of expectations due to execution challenges and continued market softness, and the company said it is taking immediate, significant action in response.

Why it matters — This update signals that Quanterix missed its revenue expectations for the quarter, which is directly relevant to those tracking the company's financial performance and near-term outlook.

FAQ

Frequently asked questions about QTRX stock

What is the QTRX stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Quanterix Corp. have a median 12-month price target of $3, with estimates ranging from $3 to $3. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is QTRX stock a buy right now?

Of the 3 analysts covering Quanterix Corp., 0 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Quanterix Corp. 28 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank QTRX?

As at 22 Aug 2026, Quanterix Corp. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (72 of 100).

Will QTRX stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +0.3% from the last close, and Ticker Nerd's factor model ranks Quanterix Corp. 28 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the QTRX stock forecast for 2030?

No analyst covering Quanterix Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QTRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $3 over the next 12 months.

How has QTRX stock performed over the past year?

Quanterix Corp. returned -38.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Quanterix Corp. do?

Quanterix Corporation, a life sciences company, is at the forefront of developing ultra-sensitive digital immunoassay technology. The company's primary function lies in innovating detection methods for biomolecules in disease research and diagnostics.

What is the latest news on QTRX?

The most recent item we track (MarketBeat, 16 Aug 2026): "Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer's Blood Test". Quanterix CEO Everett Cunningham said the company is repositioning its commercial organization and investing in diagnostics and clinical-trial capabilities following the integration of Akoya Biosciences. He also acknowledged continued market pressure in academic, government and biopharma segments.

Company

About Quanterix Corp.

Quanterix Corporation, a life sciences company, is at the forefront of developing ultra-sensitive digital immunoassay technology. The company's primary function lies in innovating detection methods for biomolecules in disease research and diagnostics. Quanterix has pioneered the Simoa technology platform, which allows scientists and clinicians to measure proteins at concentrations a thousand times lower than previously possible. This advancement is pivotal in various fields such as oncology, neurology, cardiology, and infectious diseases, providing critical data and insights for early disease detection, monitoring, and therapeutic assessment. Given its ability to deliver quantified measurements of biomarkers with unprecedented sensitivity, Quanterix plays a significant role in accelerating medical research and improving healthcare outcomes. By offering detailed molecular insights, the company's technology aids in the development of new therapies, diagnostic tools, and personalized medicine approaches, making it a vital asset in the life sciences industry.

CEO Mr. Everett V. Cunningham · 450 employees · United States · https://www.quanterix.com